Assistance From Independent Nonprofit Co-pay Foundations
Patients who are commercially and government insured (including Medicare), but need financial assistance, can be referred to independent nonprofit co-pay foundations. Amgen makes donations to these foundations that, in turn, help qualifying insured patients with out-of-pocket costs, including co-payments and premiums, to cover the medicines they need.
Amgen Assist™ can help patients identify which co-pay foundations they may be qualified for, and provide referrals for these foundations. However, Amgen Assist™ cannot guarantee that a patient will receive assistance since these co-pay foundations are independent and not affiliated with Amgen. Each foundation has its own eligibility criteria which includes an evaluation of individual’s financial, medical, and insurance status.
For more information about co-pay support or referral to an independent co-pay foundation, call one of our coverage and reimbursement services specialists at 1-800-272-9376.
NEUPOGEN® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever.
NEUPOGEN® is contraindicated in patients with known hypersensitivity to E coli-derived proteins, such as Filgrastim.
Important Safety Information
Allergic reactions occurred with initial or subsequent treatment. These have generally been characterized by systemic symptoms involving at least two body systems‚ most often skin, respiratory, and cardiovascular. Some reactions occurred on initial exposure. Reactions tended to occur within the first 30 minutes after administration and appeared to occur more frequently in patients receiving NEUPOGEN® IV.
SPLENIC RUPTURE, INCLUDING FATAL CASES, HAS BEEN REPORTED. IF PATIENTS REPORT LEFT UPPER ABDOMINAL AND/OR SHOULDER TIP PAIN, THEY SHOULD BE EVALUATED FOR AN ENLARGED SPLEEN OR SPLENIC RUPTURE.
Acute respiratory distress syndrome (ARDS) has been reported. Evaluate patients who develop fever, lung infiltrates, or respiratory distress for ARDS. If patient is diagnosed with ARDS, discontinue and/or withhold NEUPOGEN® until resolution.
Alveolar hemorrhage, manifesting as pulmonary infiltrates and hemoptysis requiring hospitalization, has been reported in healthy donors undergoing peripheral blood progenitor cell mobilization, an unapproved use of NEUPOGEN®. Hemoptysis resolved with discontinuation of NEUPOGEN®.
Severe sickle cell crises, in some cases resulting in death, have been associated with the use of NEUPOGEN® in patients with sickle cell disorders. Only physicians qualified by specialized training or experience in the treatment of patients with sickle cell disorders should prescribe NEUPOGEN® for such patients, and only after careful consideration of the potential risks and benefits.
In clinical trials involving NEUPOGEN®, bone pain was the most frequently reported adverse event.
